钙离子通道阻断剂市场：依药物类别、适应症、通路和地区划分。

预计到2026年，钙离子通道阻断剂市场规模将达到174.606亿美元，2033年将达到248.574亿美元。预计从2026年到2033年，其复合年增长率将达到5.2%。

钙离子通道阻断剂是一类用于治疗高血压、心律不整（心率不规则）和心绞痛的药物。它们透过阻断部分钙离子进入心臟和动脉发挥作用。钙离子通道阻断剂有多种剂型，从速溶片到缓释胶囊。剂量取决于患者的整体健康状况和病历。

此外，慢性肾臟病是指肾功能在数年内逐渐衰退的一种疾病。随着肾衰竭的进展和器官功能的严重受损，体内会迅速积聚危险水平的代谢废物和体液。治疗的目标是阻止或延缓疾病的进展，这通常是透过控制病因来实现的。钙离子通道阻断剂是一种用于治疗慢性肾臟病或其病因的药物。

市场动态

预计在预测期内，心血管疾病、肥胖和不健康生活方式的日益普遍将推动市场成长。

例如，根据世界卫生组织 (WHO) 2022 年的报告，2019 年估计有 1,790 万人死于心血管疾病，其中 85% 的死亡是由心肌梗塞或中风引起的。

由于新核准和核准的钙离子通道阻断剂的增加，预计市场在预测期内将显着成长。

例如，2022 年 6 月，製药公司 CMP Pharma, Inc. 获得了美国食品药物管理局 ( 食品药物管理局核准钙离子通道阻断剂患者的高血压。

本次调查的主要特点

• 本报告对全球钙离子通道阻断剂市场进行了详细分析，预测期（2026-2033 年）的市场规模和复合年增长率（%）为 2025 年为基准年。
• 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本报告根据以下参数对全球钙离子通道阻断剂市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务绩效和策略。
• 透过利用本报告中提出的见解，企业行销负责人和经营团队可以就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
• 这份全球钙离子通道阻断剂市场报告的目标受众包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师等产业相关人员。
• 相关人员可以透过利用全球钙离子通道阻断剂市场分析中使用的各种策略矩阵来简化决策过程。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场范围

• 报告摘要
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 促进因素
• 抑制因子
• 机会
• 影响分析
• 主要发展策略
• 併购情景
• 市场趋势
• 品牌分析
• 法规环境
• PEST分析
• 价格分析

第四章 全球钙离子通道阻断剂市场：依药物类别划分，2026-2033年

• 苯并噻唑烷
• 二氢吡啶
• 苯烷基胺

第五章 全球钙离子通道阻断剂市场：依适应症划分，2026-2033年

• 高血压
• 胸痛
• 心律不整
• 其他（血管疾病、冠状动脉疾病等）

第六章 全球钙离子通道阻断剂市场：依通路划分，2026-2033年

• 医院药房
• 零售药房
• 网路药房

第七章 全球钙离子通道阻断剂市场：依地区划分，2026-2033年

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • GCC
  • 以色列
  • 其他中东国家
• 非洲
• 南非
• 中非
• 北非

第八章 竞争情势

• 衝突简介
  • Bausch Health
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Arbor Pharmaceuticals
  • GlaxoSmithKline Plc
  • Biopharma
  • Sofgen Pharmaceuticals
  • Glenmark Pharmaceuticals Inc
  • Amneal Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd,
  • Novartis AG
  • Zydus Cadila
  • Pfizer Inc,

第九章

• 参考
• 调查方法

Calcium Channel Blocker Drugs Market is estimated to be valued at USD 17,460.6 Mn in 2026 and is expected to reach USD 24,857.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.

Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.

Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ's function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease - this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.

Market Dynamics

Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.

Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period

For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.

Key features of the study

• This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global calcium channel blocker drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market

Market Segmentation

• Global Calcium Channel Blocker Drugs Market, By Drug Class
  • Benzothizepine
  • Dihydropyridine
  • Phenylalkylamine
• Global Calcium channel blocker drugs market, By Disease Indication
  • Hypertension
  • Chest Pain
  • Arrhythmias
  • Others (Blood vessel conditions, Coronary Artery Disease etc.)
• Global Calcium Channel Blocker Drugs Market, By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Global Calcium Channel Blocker Drugs Market, By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • Bausch Health
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Arbor Pharmaceuticals
  • GlaxoSmithKline Plc
  • Biopharma
  • Sofgen Pharmaceuticals
  • Glenmark Pharmaceuticals Inc.
  • Amneal Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd
  • Novartis AG
  • Zydus Cadila
  • Pfizer Inc

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Drivers
• Restraints
• Opportunities
• Impact Analysis
• Key Development Strategies
• Mergers And Acquisition Scenario
• Market Trends
• Brand Analysis
• Regulatory Scenario
• PEST Analysis
• Pricing Analysis

4. Global Calcium Channel Blocker Drugs Market, By Drug Class, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Benzothizepine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Dihydropyridine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Phenylalkylamine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

5. Global Calcium Channel Blocker Drugs Market, By Disease Indication, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Hypertension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Chest Pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Arrhythmias
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Others (Blood vessel conditions, coronary artery disease etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

6. Global Calcium Channel Blocker Drugs Market, By Distribution Channel, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

7. Global Calcium Channel Blocker Drugs Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
• North America
  • Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Region/Country, 2026 - 2033, (USD Mn)
• South Africa
• Central Africa
• North Africa

8. Competitive Landscape

• Competitive Snapshot
  • Bausch Health
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Mylan N.V.
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Teva Pharmaceutical Industries Ltd
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Lupin
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Arbor Pharmaceuticals
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • GlaxoSmithKline Plc
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Biopharma
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Sofgen Pharmaceuticals
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Glenmark Pharmaceuticals Inc
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Amneal Pharmaceuticals
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Sun Pharmaceutical Industries Ltd,
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Novartis AG
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Zydus Cadila
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Pfizer Inc,
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact